title: CysLT1 receptor inhibition in patients with Raynaud's phenomenon: capillaroscopic evidence of the role of leukotriene.
abstract: OBJECTIVE
  To assess the effect of the leukotriene receptor inhibitor (montelukast) on vascular alterations in fingers of patients with Raynaud's phenomenon.
  
  
  METHODS
  Patients with Raynaud's phenomenon of the hands secondary to inflammatory connective tissue disease were selected, and those with the following characteristics were excluded: smokers, arterial hypertension, and diabetes mellitus. All patients maintained their previous medications and started the use of montelukast, 10 mg/day, for 60 days. Naifold capillaroscopy of fingers was performed before the use of medication and after 30 and 60 days. Statistical analysis was performed with percentage, media, standard deviation, Fisher exact test, with 95% of confidence interval.
  
  
  RESULTS
  The study assessed five Caucasian, female patients with Raynaud's phenomenon secondary to inflammatory connective tissue disease (three with scleroderma and two with mixed connective tissue disease), aged 42.4 ± 11.5 years, and with 9.6 ± 4.8 years of disease duration. Patients were on nifedipine and pentoxifylline, and those with mixed connective tissue disease were also on prednisone. The medications were maintained. After using montelukast for two months, nailfold capillaroscopy showed a reduction in edema and pallor, and normalization of capillary number, size, and distribution.
  
  
  CONCLUSIONS
  The use of montelukast modified the capillary abnormalities observed on nailfold capillaroscopy of patients with Raynaud's phenomenon.
authors.affiliation: Universidade Federal do Rio de Janeiro. mnazevedo@uol.com.br
authors.forename: Mario Newton Leitão de
authors.initials: MN
authors.lastname: Azevedo
authors.forename: Edda Maria T
authors.initials: EM
authors.lastname: Bernardini
authors.forename: Elizabeth F
authors.initials: EF
authors.lastname: Salles
authors.forename: Felipe
authors.initials: F
authors.lastname: Heinzmann
authors.forename: Frederico
authors.initials: F
authors.lastname: Marconde
authors.forename: Tatiana
authors.initials: T
authors.lastname: Mello
authors.forename: Blanca Elena Rios
authors.initials: BE
authors.lastname: Gomes
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000328:Adult; D003521:Cyclopropanes; D005260:Female; D006801:Humans; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D020678:Microscopic Angioscopy; D011446:Prospective Studies; D011804:Quinolines / Q000627:therapeutic use*; D011928:Raynaud Disease / Q000175:diagnosis* / Q000188:drug therapy*; D018077:Receptors, Leukotriene / Q000187:drug effects*; D013440:Sulfides
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D018077:Receptors, Leukotriene; D013440:Sulfides; C083169:leukotriene D4 receptor; C093875:montelukast